Supplementary Table 2. Other exclusion criteria

No.	Clinically significant conditions or diseases considered for the reason for exclusion of the participant
1	Current or history of hypersensitivity to any of the ingredients of study drugs (enavogliflozin or dapagliflozin), other SGLT-2 inhibitors, or metformin
2	Other type of diabetes, e.g., type 1 diabetes mellitus or secondary diabetes
3	Pregnant or lactating woman
4	Woman of childbearing potential or female partner not willing to use effective contraceptive methods
5	History of medically significant renal diseases, such as renal vascular occlusion, nephrectomy, or kidney transplant
6	History of major gastrointestinal surgery, such as total gastrectomy, total colectomy, small bowel resection, gastrointestinal anastomosis, or gastric bypass surgery
7	History of acute pancreatitis or pancreatic surgery
8	Bariatric surgery within 2 years
9	Diabetic ketoacidosis or diabetic precoma and coma within a year
10	Urinary tract infection or genital infection within a year
11	Addiction to alcohol or other substances within a year
12	Acute coronary syndrome, unstable angina, myocardial infarction requiring hospitalization, transient ischemic attack, or arrythmia within 24 weeks
13	Major surgery that caused electrolyte disturbances within 12 weeks or planned major surgery within 12 weeks after the completion of the study
14	History of, or concurrent lactic acidosis
15	Uncontrollable dysuria, anuria, oliguria, or urinary obstruction due to stress urinary incontinence, neurogenic bladder, or prostatic hyperplasia
16	Severe diabetes complications such as proliferative diabetic retinopathy, stage 4 nephropathy, or severe diabetic neuropathy
17	Chronic diseases to be treated with prolonged use of diuretics, systemic steroids, or immunosuppressive drugs
20	Hypopituitarism or adrenal insufficiency
21	Serious infection or clinically significant injury
22	Unstable mental disease that could not be managed with drugs
23	Severe gastrointestinal diseases such as active peptic ulcer, gastrointestinal/rectal bleeding, active inflammatory bowel syndrome, biliary obstruction, or active gastritis
24	Severe liver disease, defined as one of the following conditions: • Total bilirubin > twice upper limit of normal • Hepatitis or liver failure
25	Severe hypertriglyceridemia (triglyceride >500 mg/dL)
26	Acquired immunodeficiency syndrome
27	Pulmonary infarction, severe pulmonary insufficiency, or conditions frequently accompanied with hypoxia
28	Severe dehydration due to diarrhea or vomiting, or having a risk of body fluid depletion
29	Genetic conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
30	History of malignant tumor within 5 years (patients with basal cell carcinoma, squamous cell skin cancer, carcinoma *in situ* of cervix, or cured cancer [in remission] for more than 5 years were allowed to participate in the study)
31	Changed the dose of thyroid medication within 6 weeks (thyroid medication was allowed during the study only if it had been administered at a stable dose or at reduced dose for stable condition)
32	Use of other investigational product/device 4 weeks before screening

SGLT-2, sodium-glucose cotransporter 2.